This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
By This Author:
« Back
Page 1 of 23

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

By Adam Feuerstein

Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.

10:39AM 03/24/15

Celgene's Crohn's Disease Drug Candidate Highlighted in NEJM

By Adam Feuerstein

Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.

05:00PM 03/18/15

Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals

By Adam Feuerstein

When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.

10:26AM 03/17/15

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

By Adam Feuerstein

The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.

09:36AM 03/13/15

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

By Adam Feuerstein

Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.

10:45AM 03/11/15

Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear

By Adam Feuerstein

Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.

10:17AM 03/10/15

Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer

By Adam Feuerstein

The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.

01:47PM 03/04/15

MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter

By Adam Feuerstein

Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.

08:15AM 03/02/15

Ampio Too Busy to Tell Investors Results of Eye Drug Study

By Adam Feuerstein

Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.

07:55AM 02/25/15

Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus

By Adam Feuerstein

The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.

03:47PM 02/20/15

« Back
Page 1 of 23

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,664.48 -13.75 -0.08%
S&P 500 2,055.95 -0.20 -0.01%
NASDAQ 4,865.5530 +2.1910 0.05%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs